Market Overview

ICYMI: Valeant, Overstock And Biotechs

Related GRPN
20 Stocks Moving In Wednesday's Pre-Market Session
Jim Cramer Advises His Viewers On Groupon, Adobe And More
Related REGN
Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect
The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
Regeneron adds to breakout, up 2% (Seeking Alpha)

In case you missed it, here are some of Benzinga's top stories from Monday, March 5, 2018.

A Valeant Bear Relents

Learn what finally convinced Deutsche Bank’s Gregg Gilbert to grant a buy rating to Valeant Pharmaceuticals Inc (NYSE: VRX) in Elizabeth Balboa’s “How Valeant Finally Won Over A Longtime Bear.”

Overstock Bull Sharpens His Horns Ahead Of ICO

Despite last week’s SEC scare, Inc (NASDAQ: OSTK) is still a hot stock with plenty of upside, according to D.A. Davidson. Get some background on this bull’s thesis in Wayne Duggan’s “Analyst Stays Bullish On Overstock's tZERO Coin Offering Despite Regulatory Risk.”

Related Link: Morgan Stanley Says Groupon's 16% Decline In 2018 Is 'Overdone'

Keep Your Eyes Peeled For These 7 Biotechs In March

From Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to ImmunoGen, Inc (NASDAQ: IMGN), several biotechs are expected to release meaningful updates on their clinical programs this month. Shanthi Rexaline has the details.

Latest Ratings for GRPN

May 2018UBSUpgradesSellNeutral
Mar 2018Morgan StanleyUpgradesUnderweightEqual-Weight
Feb 2018JP MorganMaintainsNeutralNeutral

View More Analyst Ratings for GRPN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Cryptocurrency News Previews After-Hours Center Markets Analyst Ratings


Related Articles (IMGN + GRPN)

View Comments and Join the Discussion!